BPC-157 vs NAD+ at Youth Lab Peptides
Similar longevity hopes, different substances and experiments. The comparison becomes useful once the actual outcome replaces the general promise.
BPC-157 and NAD+: repair and metabolism
The BPC-157 review describes a largely preclinical repair literature and very limited human evidence. The NAD+ review concerns precursor supplementation in human aging, with reliable blood changes and much less certain clinical benefit. One compound’s result cannot stand in for the other’s.
BPC-157 is a synthetic peptide based on gastric protein material. NAD+ is a coenzyme, a helper molecule used in cellular reactions. Oral NMN and NR supply material from which cells make NAD+. In the human evidence discussed here, the studies used those precursors rather than treating every NAD+ route as interchangeable.
I understand why “BPC 157 and NAD” sounds like a plausible pairing: repair needs energy. A plausible connection can generate an experiment. There is no controlled human combination study in this record showing the benefit or safety of BPC-157 with NAD+. My interest would begin with that actual experiment, including later follow-up.
The outcomes beside one another
| Compound | A result actually measured | The next unresolved question |
|---|---|---|
| BPC-157 | Safety markers in two healthy adults | Human injury repair and long-term safety |
| NAD+ precursors | Blood NAD+ over 8 weeks with NR | Durable improvements in health and function |
| Semaglutide | Cardiovascular outcomes in SELECT | Application beyond the specific patient population |
| Thymosin alpha-1 | Day-28 mortality in TESTS | Where benefit can be established after a null sepsis trial |
I wouldn’t rank these on a single youthfulness scale. The endpoints describe different events in different populations. The most mature clinical evidence here is semaglutide’s, for the particular conditions studied. That makes it substantial evidence for those uses rather than evidence for every compound collected under a longevity label.
Comparisons that have actually been run
SURMOUNT-5 assigned adults with obesity to tirzepatide or semaglutide. That head-to-head design measured both treatments within a common trial. BPC-157 vs NAD+ has no equivalent controlled human comparison in these papers. Neither does the proposed combination.
For “Biopro+ vs BPC-157,” the reading list contains no study of Biopro+. A comparison of efficacy, ingredients or safety would require evidence outside this list. The necessary evidence is absent here.
“Thymosin Labs BPC 157” also combines names without specifying an experiment. The substances covered here are distinct: BPC-157 has gastric origins and repair experiments; thymosin alpha-1 has thymic origins and immune research. No benefit follows from placing the names alongside each other.
U.S. regulatory status
Semaglutide has FDA-approved prescription forms for specified uses; compounded medicines are not FDA-approved. NAD+ precursor supplements and wellness infusions have no FDA approval to treat a specific illness, and FDA has disputed NMN’s eligibility for the dietary-supplement category.
BPC-157 and thymosin alpha-1 lack FDA approval. On FDA’s page current as of April 22, 2026, both appear among withdrawn nominations for compounding. Withdrawal confers neither approval nor Category 1 listing. The page supplies no date for a move out of Category 2; the date describes the page snapshot. FDA’s concerns include immunogenicity, meaning unwanted immune reactions, and peptide-related impurities.
A licensed provider and pharmacy must assess whether an individual preparation is appropriate and permitted. That review establishes no FDA approval. The full compound pages distinguish these regulatory questions from the trials and from anecdotal experience.